rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CELU
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Celularity partners with Vesalius for peptide manufacturing
      Oct 29Investing.comCELU
      Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States
      Oct 29Yahoo FinanceCELU
      Celularity regains Nasdaq compliance after late filing
      Oct 22Investing.comCELU
      Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
      Oct 22Yahoo FinanceCELU
      Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner

      Fontaine Vitale represents a significant new market and revenue opportunity for Celularity in the Asia-Pacific regionFLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today highlighted continued progress at Fontaine Vitale, a regenerative medicine and wellness center being developed in the Sanur Special Economic Zone

      Sep 30Yahoo FinanceCELU
      Celularity adds Viome CEO Naveen Jain to board of directors
      Sep 29Investing.comCELU
      Celularity Announces Naveen Jain to Join Board of Directors
      Sep 29Yahoo FinanceCELU
      Celularity Secures New Convertible Note Financing and Board Shift

      Detailed price information for Celularity Inc (CELU-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailCELU
      Celularity announces $25 million convertible note financing and board changes
      Sep 28Investing.comCELU
      Celularity raises over $10M in debt financing, targets cash flow positive by Q1 2027
      Sep 24Investing.comCELU
      Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
      Sep 24Yahoo FinanceCELU
      Celularity Restores Nasdaq Compliance on Key Listing Standards

      Detailed price information for Celularity Inc (CELU-Q) from The Globe and Mail including charting and trades.

      Sep 15The Globe and MailCELU
      Celularity regains Nasdaq compliance for bid price and market value
      Sep 14Investing.comCELU
      Why Is Celularity Stock Gaining Thursday?
      Aug 27BenzingaCELU
      12 Health Care Stocks Moving In Thursday's Intraday Session
      Aug 27BenzingaCELU
      Celularity Signs U.S. Manufacturing Collaboration With Potential $300 Million Purchase Opportunity

      Celularity’s new manufacturing collaboration with MuseCell Innovations is intended to establish U. S.

      Aug 27Yahoo FinanceCELU
      Celularity to manufacture Dezawa MuseCells for MuseCell Innovations
      Aug 27Investing.comCELU
      Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
      Aug 27Yahoo FinanceCELU
      Celularity Provides Update Regarding Nasdaq Listing Compliance

      FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC stating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026 and remains delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in compli

      Aug 25Yahoo FinanceCELU

      This is the newest page. Registered accounts read further back.